Tech lobbying groups file lawsuit against nation’s first digital advertising tax
Organizations representing tech titans like Google and Facebook claim the Maryland law represents “legislative overreach.”
Lobbying
PCMA appoints AdvaMed veteran J.C. Scott as CEO
Outgoing Pharmaceutical Care Management Association chief executive Mark Merritt is stepping down after 15 years.
Bigelow to succeed Kamp as head of Coalition for Healthcare Communication
John Kamp has served as the group’s executive director for 16 years.
From working for one administration to fending off another: Planned Parenthood’s Kevin Griffis
Kevin Griffis brought his experience in government and politics to Planned Parenthood at the perfect time, leading the fight to protect birth control coverage under the Trump administration and destigmatizing abortion.
Five things for pharma marketers to know: Tuesday, December 19, 2017
Pharma industry spent $57 million on lobbying in 2016; Humana, private equity firms to buy Kindred for $4 billion; price of old glaucoma drug skyrockets
Limits on pharma payments to doctors back on policy menu
A mini wave of state-level rule-making has thrust the issue of restrictions on pharma payments to medical professionals back into the spotlight.
Five things for pharma marketers to know: Tuesday, April 11, 2017
Groups with PhRMA ties warn against drug-pricing proposals; patients learn how to be advocates; the U.K. will not cover Opdivo for head and neck cancer
Five things for pharma marketers to know: Thursday, October 27, 2016
BIO released a video explaining drug costs; the FDA commits to shorter generic approval process; Kaléo to launch EpiPen competitor
Five things for pharma marketers to know: Friday, July 15, 2016
PhRMA brings on new members, Amgen partners with Daiichi Sankyo on biosimilar commercialization in Japan; Thomson Reuters to sell science unit
Five things for pharma marketers to know: Friday, March 4, 2016
New PhRMA CEO issues policy strategy; study assess patient response to immuno-oncology drugs; Twitter may be an effective way to talk about clinical trials
